You can view the page at http://forums.phoenixrising.me/content.php?548-Ottawa
Awesome article with terrific broad overview, thank you Cort.
Al'
Psychol Med. 2011 Dec 9:1-13. [Epub ahead of print]
Molecular signatures of peripheral blood mononuclear cells during chronic interferon-? treatment: relationship with depression and fatigue.
Felger JC, Cole SW, Pace TW, Hu F, Woolwine BJ, Doho GH, Raison CL, Miller AH.
BACKGROUND:
Interferon-alpha (IFN-?) treatment for infectious disease and cancer causes high rates of depression and fatigue, and has been used to investigate the impact of inflammatory cytokines on brain and behavior. However, little is known about the transcriptional impact of chronic IFN-? on immune cells in vivo and its relationship to IFN-?-induced behavioral changes.MethodGenome-wide transcriptional profiling was performed on peripheral blood mononuclear cells (PBMCs) from 21 patients with chronic hepatitis C virus (HCV) either awaiting IFN-? therapy (n=10) or at 12 weeks of IFN-? treatment (n=11).
RESULTS:
Significance analysis of microarray data identified 252 up-regulated and 116 down-regulated gene transcripts. Of the up-regulated genes, 2'-5'-oligoadenylate synthetase 2 (OAS2), a gene linked to chronic fatigue syndrome (CFS), was the only gene that was differentially expressed in patients with IFN-?-induced depression/fatigue, and correlated with depression and fatigue scores at 12 weeks (r=0.80, p=0.003 and r=0.70, p=0.017 respectively).
Promoter-based bioinformatic analyses linked IFN-?-related transcriptional alterations to transcription factors involved in myeloid differentiation, IFN-? signaling, activator protein-1 (AP1) and cAMP responsive element binding protein/activation transcription factor (CREB/ATF) pathways, which were derived primarily from monocytes and plasmacytoid dendritic cells. IFN-?-treated patients with high depression/fatigue scores demonstrated up-regulation of genes bearing promoter motifs for transcription factors involved in myeloid differentiation, IFN-? and AP1 signaling, and reduced prevalence of motifs for CREB/ATF, which has been implicated in major depression.
CONCLUSIONS:
Depression and fatigue during chronic IFN-? administration were associated with alterations in the expression (OAS2) and transcriptional control (CREB/ATF) of genes linked to behavioral disorders including CFS and major depression, further supporting an immune contribution to these diseases.
I wish some more of the recognized names in ME research would do more in this area. There is rightly a lot of research done on the immune system but I think more could be done on the brain. I've been thinking for a while that advances will probably come from a different field such as research into autism, MS, Alzheimers, etc. It's discouraging and surprising that there isn't a whole lot to show in those diseases that have been recognized to have damage to the brain; and they receive so much more funding.
Dr. Miller wasnt sure, though, that whatever started the problem is still there, and he talked about an alternative culprit to pathogens. Studies have shown that immune activation can trigger the methylation process to turn genes on or off permanently causing what is called epigenetic changes.
That's very interesting - do you have a reference? The MRC recently agreed funding for a UK study on fatigue and IFN-alpha (which I blogged about here).A recent Miller paper suggested that the same processes occurring in IFN-a induced fatigue in hepatitis may be occurring in ME/CFS. Tying the fatigue processes in hepatitis C treatment and ME/CFS together would be a huge boost for ME/CFS
That's an awfully small sample for gene expression profiling, especially using a genome-wide chip, where false positives are very likely because of the huge number of genes analysed. The Lights, who have significantly larger samples in their work, use Quantitative Real-Time PCR (QT-PCR) to measure transciption, which is a more accurate process than microarrays. Best practice is, apparently, to use microarray chips (on larger samples) to identify interesting genes then follow-up with QT-PCR on those interesting genes. So this study is an intriguing pointer, but I'm not sure its any more than that at this stage.Genome-wide transcriptional profiling was performed on peripheral blood mononuclear cells (PBMCs) from 21 patients with chronic hepatitis C virus (HCV) either awaiting IFN-? therapy (n=10) or at 12 weeks of IFN-? treatment (n=11).
I certainly agree that when we finally do crack ME it will involve a breakthrough in understanding how the body/brain works. Whatever the 'thing' is that is broken in ME/CFS is, I strongly suspect it is something that is largely unknown to medicine today.(Can't help thinking just how much ME is advancing the whole of medical understanding).
Maybe we shouldn't be so surprised, or discouraged: the brain is regularly described as 'the last great frontier in biology' and is easily the most complex thing in the known universe - so getting anywhere is not going to be easy.It's discouraging and surprising that there isn't a whole lot to show in those diseases that have been recognized to have damage to the brain; and they receive so much more funding.
I am glad researchers are seriously looking at methylation as one of the culprits. Global hypomethylation with local hypermethylation is one characteristic on cancer, for instance. I am convinced, thanks to Rich Van Konynenburg, that normalizing methylation is one of the most important steps in the path to recovery.
By the way, Rich Van Konynenburg generally hangs out in the "Detox: Methylation\B12\Glutathione\Chelation\..." forum.
Thanks for all that. Generally, the more data you have, the easier it is to see the real signal (gene, factor, whatever) against the 'noise' (false positives) - it's a statistics thing.Thanks Oceanblue,
Miller was just a great guy - he was very willing to talk and obviously very interested in the subject. It would have been great to have you there to make sense of it all
Don't know about the date of the paper - it will certainly be this year - the CDC has already stated that - but don't know when.
Thanks for insight on the sample size - something I often don't think to check. I imagine that its all pretty exploratory until we get big sample sizes and multiple validations. I wonder how in the world with all that data they will be able to zero on the same factor or gene.......
Also pleased to see Behan and Chaudhri getting a mention. Ten years! Blimey. Just goes to show that the ball may have been dropped but has now perhaps bounced (hopefully)
What does any of this mean in terms of tests we and order and treatments that can be prescribed to us... today? Time is running out, my condition only worsens year by year, and there's no telling how much of the damage is recoverable.
You are avoiding me Cort - great guys or not is of no relevance - this is not a popularity poll. THIS is about the scientific/medical understanding of a disease known as ME/CFS - sorry. Stick with science/findings. And try not to expose your own personal animosities against those who tried/try to unravel.
And the poor rats - try amygdela training .
Why are you so foolish. Have you not known the very worst. Obviously not.